That's what Will Lewis is talkng about in Cancord presentation. Additional data underway! FDA will be comfortable with this additional data to file for NDA. This additional data is not needed, but will be icing on the cake!
Q about pricing... NTM significantly higher then CF
Q endpoint... 12 weeks improvement
Q other indications.... It is front of mind of NIH
Q CF comercialization... Full speed ahead... More data in Octobre at NACF
Q Gilead and Novartis... Gilead is a no brainer, Novartis dependent on treatment... 600 milion luring